As a community service, below we list opportunities for individuals to participate in research studies. These studies may offer low or no cost treatment. Please note that these studies are not affiliated with Plotkin and Associates in any way.
New OCD Treatment Study!!!
There have not been any new medications for the treatment of refractory OCD for the last 20 years and there is finally one new agent that is promising and with an interesting mechanism of action. The proposed study is based on recent preclinical, clinical, genetic and neuroimaging studies that implicate glutamatergic hyperactivity in the pathogenesis of OCD. In multiple published clinical case studies, the use of agents that modulate brain glutamate have been suggested to have efficacy in patients with refractory OCD [1, 3-8] .
The drug we are testing is a novel glutamate modulating drug that is being developed for the potential treatment of OCD as adjunctive therapy to standard of care treatments in subjects who have experienced an inadequate response to current pharmacotherapy. Every prominent OCD Center participates in this study including Harvard (MGH) and Yale Center.
The drug is a tripeptide prodrug of the glutamate modulating agent riluzole that has been optimized for improved bioavailability, pharmacokinetics and dosing.
We are looking for:
Male and female outpatient subjects between the ages of 18 – 65 years, inclusive, with a primary DSM-V diagnosis of Obsessive Compulsive Disorder (confirmed by the MINI) who have had an inadequate response to Standard of Care medications, including their current standard of care. An inadequate response to their current standard of care is defined by a Yale–Brown Obsessive Compulsive Scale (Y-BOCS) score of 19 or greater despite at least 10 weeks of treatment at Baseline  with the maximum tolerated dose of an SSRI or clomipramine. Additionally, OCD symptoms in subjects had to be present for ≥ 1 year and at least of moderate severity on the Clinical Global Impression Scale severity of illness item. The study takes 12 weeks and then responders continuing on the medication for 48 weeks.
This is new outstanding research. Please refer the patients to CalNeuroResearch Group. Call: 310-208-7144